TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20402570

Group type: EXPERIMENTAL
Intervention: Odor identification ability measured by the University of Pennsylvania Smell Identification Test (SIT) during 24 hr of sleep deprivation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Performance on the Wisconsin Card Sorting Test (WCST) following 45 hr of wakefulness
Number of subjects: 54
Study: 18326617

Group type: EXPERIMENTAL
Intervention: Calcium- and vitamin D3-fortified milk
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no fortified milk provided)
Number of subjects: 109
Study: 16122470

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (28 degrees C)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normothermic CPB (35‐37 degrees C)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 12462697

Group type: EXPERIMENTAL
Intervention: High-volume fiber-reinforced composite substructure
Number of subjects: 39

Group type: COMPARATOR
Intervention: Low-volume fiber-reinforced composite substructure
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All surviving prostheses
Number of subjects: 39
Study: 10204379

Group type: EXPERIMENTAL
Intervention: Acupuncture treatments in addition to non-steroidal anti-inflammatory drugs and intraarticular administration of glucocorticosteroids and inhibitors of proteases
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs together with intraarticular administration of glucocorticosteroids and inhibitors of proteases
Number of subjects: 40
Study: 2569279

Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg vecuronium bromide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 micrograms/kg vecuronium bromide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 300 micrograms/kg vecuronium bromide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg vecuronium bromide
Number of subjects: 40
Study: 943758

Group type: EXPERIMENTAL
Intervention: Localized fatigue of knee and hip flexors and extensors
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Localized fatigue of dorsi flexors, abdominals, plantar flexors
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (practice period and 3 performance trials)
Number of subjects: 100
Study: 31659776

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study: 31227279

Group type: EXPERIMENTAL
Intervention: Intensive sit-to-stand training in addition to usual care
Number of subjects: 30
Study: 28095046

Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 1,800 IU
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25524395

Group type: EXPERIMENTAL
Intervention: Time framed as dates (e.g., June 1st, 2015)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time framed as days (e.g., 5000 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calendar method
Number of subjects: 0
Study: 23748948

Group type: EXPERIMENTAL
Intervention: Silver zinc sulfadiazine with added sericin cream
Number of subjects: 29

Group type: COMPARATOR
Intervention: Silver zinc sulfadiazine cream (control)
Number of subjects: 29
Study: 21880194

Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLF) 70 mg/day
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no bLF)
Number of subjects: 172
Study: 19583651

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 18
Study: 17845952

Group type: EXPERIMENTAL
Intervention: Clinical pathway for managing UTIs in LTCFs, including decision tools for urine culture and antibiotic treatment initiation.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Clinical pathway for managing UTIs in LTCFs.
Number of subjects: 71
Study: 15161831

Group type: EXPERIMENTAL
Intervention: Dilated high-density scanning (512 A-scans per image)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dilated standard-density scanning (128 A-scans per macular and ONH image)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dilated standard-density scanning
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard-density scanning
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dilated high-density scanning
Number of subjects: 10
Study: 11295629

Group type: EXPERIMENTAL
Intervention: Various clinical/statistical designs including high-risk populations, randomization, surrogate endpoints, quality-of-life endpoints, masking/blinding, and adaptive designs.
Number of subjects: 32400
Study: 9533468

Group type: EXPERIMENTAL
Intervention: Cefixime suspension 8 mg/kg/day bd for 10 days
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav suspension 80 mg/kg/day tds for 10 days
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 501
Study: 7914121

Group type: EXPERIMENTAL
Intervention: Proxodolol 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Proxodolol 80 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol 80 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2970337

Group type: EXPERIMENTAL
Intervention: PTCA with larger balloon
Number of subjects: 336

Group type: COMPARATOR
Intervention: PTCA with smaller balloon
Number of subjects: 336
Study: 620480

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (up to 42 mg/day)
Number of subjects: 6
Study: 31152686

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Conventional protocol
Number of subjects: 276
Study: 28919011

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day plus oral trametinib 2 mg once per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 36
Study: 25553889

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brodalumab (doses unspecified)
Number of subjects: 0
Study: 23421838

Group type: EXPERIMENTAL
Intervention: Family Check‐Up (FCU) intervention
Number of subjects: 998
Study: 22267018

Group type: EXPERIMENTAL
Intervention: Oral tenofovir and emtricitabine/tenofovir PrEP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 60
Study: 20823620

Group type: EXPERIMENTAL
Intervention: Distilled Water (DW)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS)
Number of subjects: 2
Study: 17697200

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg q.d.s.
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg b.d.
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1184
Study: 15767053

Group type: EXPERIMENTAL
Intervention: Digital non-stereo color fundus photographs
Number of subjects: 118
Study: 12212928

Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine/nelfinavir
Number of subjects: 142

Group type: COMPARATOR
Intervention: zidovudine/lamivudine/nevirapine
Number of subjects: 142
Study: 9866186

Group type: EXPERIMENTAL
Intervention: Emotional writing with thought suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional writing without thought suppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thought suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonemotional writing
Number of subjects: 0
Study: 8564344

Group type: EXPERIMENTAL
Intervention: ECG monitoring during bronchoscopy (30 min before, during, and 30 min after)
Number of subjects: 100
Study: 2652168

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg) with haloperidol (8 mg) pretreatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Placebo with haloperidol (8 mg) pretreatment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg) with placebo pretreatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo with placebo pretreatment
Number of subjects: 5
Study: 728284

Group type: EXPERIMENTAL
Intervention: Intravenous disopyramide (2 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral disopyramide (Rythmodan and Norpace, 300 mg)
Number of subjects: 8
Study: 31870614

Group type: EXPERIMENTAL
Intervention: Planmeca Emerald
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Medit i500
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3Shape A/S TRIOS 3
Number of subjects: 19

Group type: COMPARATOR
Intervention: Planmeca
Number of subjects: 19
Study: 31055993

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 773

Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 773

Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 773

Group type: COMPARATOR
Intervention: Advanced stage
Number of subjects: 773

Group type: COMPARATOR
Intervention: Older age
Number of subjects: 773

Group type: COMPARATOR
Intervention: Male gender
Number of subjects: 773

Group type: COMPARATOR
Intervention: Preexisting stroke
Number of subjects: 773
Study: 28215452

Group type: EXPERIMENTAL
Intervention: Intraocular lens implantation
Number of subjects: 43
Study: 25737192

Group type: EXPERIMENTAL
Intervention: 20/5mg prasugrel
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: 20/3.75mg prasugrel
Number of subjects: 422

Group type: COMPARATOR
Intervention: 300/75mg clopidogrel
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: 20/3.75mg prasugrel (high-risk group)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: 20/2.5mg prasugrel (high-risk group)
Number of subjects: 422

Group type: COMPARATOR
Intervention: 300/75mg clopidogrel (high-risk group)
Number of subjects: 422
Study: 23643256

Group type: EXPERIMENTAL
Intervention: Etanercept + Clobetasol Propionate (CP) foam
Number of subjects: 592

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 592
Study: 22167437

Group type: EXPERIMENTAL
Intervention: Intravenous sedation with local anesthesia (sedation group, n = 123)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Local anesthesia only (nonsedation group, n = 132)
Number of subjects: 255
Study: 19209092

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Hexavalent vaccine
Number of subjects: 403
Study: 16680757

Group type: EXPERIMENTAL
Intervention: RBC life span measurement via breath carbon monoxide concentration in rheumatoid arthritis subjects
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: RBC life span measurement via breath carbon monoxide concentration in anemic hospitalized patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: RBC life span measurement via breath carbon monoxide concentration in osteoarthritis subjects
Number of subjects: 3
Study: 15320685

Group type: EXPERIMENTAL
Intervention: Resistance training program (2 months, 6 exercises, 3 x 10 repetitions maximum, 3 times per week)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Detraining (2 months after training)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hormonal responses (testosterone, sex hormone binding globulin, free androgen index)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation analysis of hormonal responses and strength changes
Number of subjects: 19
Study: 11280341

Group type: EXPERIMENTAL
Intervention: Exposure in vivo plus response prevention
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Waiting‐list control condition
Number of subjects: 78
Study: 9031463

Group type: EXPERIMENTAL
Intervention: RO-11 at a dose of 7,500 anti-FXa i.u. (110 anti-FXa i.u./Kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RO-11 at doses of 9,000 and 12,500 anti-FXa i.u.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RO-11 (all doses)
Number of subjects: 0
Study: 8034236

Group type: EXPERIMENTAL
Intervention: Heparin (calcium heparin, 12,500 IU in 0.5 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (0.5 ml)
Number of subjects: 10
Study: 2831127

Group type: EXPERIMENTAL
Intervention: Lovastatin (Mevinolin)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 24
Study: 31352853

Group type: EXPERIMENTAL
Intervention: SQ tree sublingual immunotherapy (SLIT)-tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30279504

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg/fenofibric acid 135mg for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Atorvastatin 20mg for 12 weeks
Number of subjects: 37
Study: 27163694

Group type: EXPERIMENTAL
Intervention: Rapid initiation arm (single-visit ART initiation)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Rapid initiation arm
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard initiation arm (standard clinic procedures)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard initiation arm
Number of subjects: 377
Study: 24508445

Group type: EXPERIMENTAL
Intervention: Improved BMI category
Number of subjects: 2069

Group type: EXPERIMENTAL
Intervention: Remained obese or worsened relative weight group
Number of subjects: 2069

Group type: COMPARATOR
Intervention: No change in relative weight category
Number of subjects: 2069
Study: 22951082

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent (E-ZES)
Number of subjects: 8709

Group type: COMPARATOR
Intervention: Cypher sirolimus-eluting stent (C-SES)
Number of subjects: 8709
Study: 19493585

Group type: EXPERIMENTAL
Intervention: Docetaxel 75mg/m² and carboplatin AUC 6 with zoledronic acid 4mg every 3 weeks for 6 cycles (Arm A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Docetaxel 75mg/m² and carboplatin AUC 6 without zoledronic acid (Arm B)
Number of subjects: 150
Study: 18521047

Group type: EXPERIMENTAL
Intervention: Unopposed estrogen (conjugated estrogens 0.625 mg)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Estrogen plus 2.5 mg of medroxyprogesterone acetate
Number of subjects: 309

Group type: COMPARATOR
Intervention: HT (combined unopposed estrogen and estrogen plus medroxyprogesterone acetate)
Number of subjects: 309
Study: 15570623

Group type: EXPERIMENTAL
Intervention: Joint modelling of baseline and outcome variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighting for complete cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deterministic imputation using other baseline variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dummy variable for missingness
Number of subjects: 0
Study: 11987041

Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Two equal Tono-Pens
Number of subjects: 100
Study: 11094929

Group type: EXPERIMENTAL
Intervention: New nursing care delivery system including unlicensed assistive personnel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard nursing care without unlicensed assistive personnel)
Number of subjects: 0
Study: 7586303

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg daily)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Sulotroban (800 mg QID)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 752
Study: 2253659

Group type: EXPERIMENTAL
Intervention: Theophylline (Th) 450-900 mg in the evening
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terbutaline (Te) 7.5 mg twice daily
Number of subjects: 9
Study: 6992980

Group type: EXPERIMENTAL
Intervention: Elective radical neck dissection
Number of subjects: 75

Group type: COMPARATOR
Intervention: Therapeutic radical neck dissection
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Comparison of survival curves
Number of subjects: 75
Study: 31913150

Group type: EXPERIMENTAL
Intervention: Intervention group (received feedback)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 92
Study: 30527586

Group type: EXPERIMENTAL
Intervention: Modified flowable RMGIC (ACTIVA Bioactive; AB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nanofilled resin composite (CeramX; RC)
Number of subjects: 67
Study: 28809989

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% topical suspension (Taclonex® TS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Betamethasone Dipropionate 0.05% lotion (Diprosone®)
Number of subjects: 10
Study: 25862439

Group type: EXPERIMENTAL
Intervention: Dynamic prediction using a nomogram for 5-year dynamic overall survival (DOS)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: High-risk N-stage (N2/3)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Locoregional recurrence (LRR)
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: HER2 positivity
Number of subjects: 2602

Group type: EXPERIMENTAL
Intervention: Treatment discontinuation
Number of subjects: 2602
Study: 22537100

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone ER 16 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22027196

Group type: EXPERIMENTAL
Intervention: Burr hole drainage with irrigation (Group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Burr hole drainage alone (Group A)
Number of subjects: 92
Study: 19520987

Group type: EXPERIMENTAL
Intervention: Ropinirole + Physiotherapy (PT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo + Physiotherapy (PT)
Number of subjects: 33
Study: 16452067

Group type: EXPERIMENTAL
Intervention: Stavudine ER
Number of subjects: 29

Group type: COMPARATOR
Intervention: Stavudine IR
Number of subjects: 29
Study: 14524017

Group type: EXPERIMENTAL
Intervention: Standardized medical care system for children with severe thermal lesions
Number of subjects: 473
Study: 10550565

Group type: EXPERIMENTAL
Intervention: Formulation B (test formulation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Formulation A (reference formulation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 25
Study: 8911828

Group type: EXPERIMENTAL
Intervention: Moderate endurance training (12 weeks, 30 min at 65‐70% of VO2max, 4‐5 days/week)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate endurance training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute exercise post-training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recombinant IL-2 (rIL-2) addition to stimulated cultures
Number of subjects: 15
Study: 2064484

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) combined with behavior modification
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard behavior therapy program
Number of subjects: 36
Study: 6225396

Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (0.5 to 1.0 mg/kg/day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Isotretinoin therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3
Study: 31662866

Group type: EXPERIMENTAL
Intervention: XG + PPT + XOS
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29920532

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 10
Study: 26684150

Group type: EXPERIMENTAL
Intervention: rhPTH(1‐84) 50 μg/day, escalated to 75 and then to 100 μg/day if needed
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rhPTH(1‐84)
Number of subjects: 24
Study: 24162168

Group type: EXPERIMENTAL
Intervention: Transanal drainage tube (TDT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Metallic stent
Number of subjects: 29
Study: 22154609

Group type: EXPERIMENTAL
Intervention: Combined ED‐saving strategy including prospective ECG triggering with a short x‐ray window and a BMI‐adapted imaging protocol using adaptive statistical iterative reconstruction (ASIR)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Prospective ECG triggering strategy alone
Number of subjects: 156
Study: 19160156

Group type: EXPERIMENTAL
Intervention: Monopolar forceps via TGA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Monopolar forceps via TVA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Forced argon plasma coagulation (FAPC) via TGA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Forced argon plasma coagulation (FAPC) via TVA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TGA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FAPC for additional treatment of bleeding from the main gastroepiploic artery via TVA
Number of subjects: 12
Study: 17394035

Group type: EXPERIMENTAL
Intervention: tamsulosin
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: alfuzosin
Number of subjects: 64
Study: 15723023

Group type: EXPERIMENTAL
Intervention: Patients with MDD and concurrent SUD symptoms
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Patients without concurrent SUD symptoms
Number of subjects: 1484
Study: 12572379

Group type: EXPERIMENTAL
Intervention: Jietongyin Lotion (JTYL)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Rishu an Lotion (Control)
Number of subjects: 360
Study: 9467475

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg twice daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Tolterodine dosages of ≤ 2 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 7637351

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 316

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion
Number of subjects: 316